Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 7/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PARG | Q86W56 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11447330 | 0.93 | MEN1 (0.49) | MEN1KMT2APKMSMN1; SMN2ATG4B | |
| SCHEMBL11440932 | 0.88 | ATG4B (0.51) | MEN1KMT2APKMSMN1; SMN2ATG4B | |
| SCHEMBL11435038 | 0.83 | ATG4B (0.49) | MEN1KMT2APKMSMN1; SMN2ATG4B | |
| SCHEMBL10340123 | 0.82 | ATG4B (0.43) | ATG4BKLK7BRD4ATAD2MALT1 | |
| Hydrochloric Acid SCHEMBL10340135 | 0.81 | ATG4B (0.42) | ATG4BKLK7BRD4ATAD2MALT1 | |
| SCHEMBL11435578 | 0.80 | MEN1 (0.57) | MEN1KMT2APKMSMN1; SMN2ATG4B | |
| SCHEMBL11440845 | 0.77 | NPSR1 (0.46) | MEN1KMT2APKMSMN1; SMN2ATG4B | |
| SCHEMBL9623183 | 0.76 | KDM4E (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11434865 | 0.76 | NPSR1 (0.45) | MEN1KMT2APKMSMN1; SMN2ATG4B | |
| SCHEMBL11447415 | 0.76 | MEN1 (0.45) | MEN1KMT2APKMSMN1; SMN2ATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5183821-A | Administering anticarcinogenic agents | LABORATORIES KNOLL, S.A. (ES) | 1993-02-02 | — | — | US | claimed |
| EP-1626050-B1 | SULFUR-CONTAINING NAPHTHOYLIMIDE DERIVATIVES | UNIV EAST CHINA SCIENCE & TECH (CN) | 2009-12-02 | — | — | EP | disclosed |
| US-7541463-B2 | Sulfur-containing naphthalimide derivatives | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2009-06-02 | — | — | US | disclosed |
| US-20080234287-A1 | SULFUR-CONTAINING NAPHTHALIMIDE DERIVATIVES | QIAN XUHONG | 2008-09-25 | — | — | US | disclosed |
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-24 | — | — | US | disclosed |
| EP-1787985-A1 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | Unibioscreen S.A. (BE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1742920-A2 | NAPHTHALIMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Unibioscreen S.A. (BE) | 2007-01-17 | — | — | EP | disclosed |
| US-20060111367-A1 | Sulfur-containing naphthalimide derivatives | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCE (CN) | 2006-05-25 | — | — | US | disclosed |
| EP-1626050-A1 | SULFUR-CONTAINING NAPHTHOYLIMIDE DERIVATIVES | East China University of Science and Technology (CN) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005105753-A2 | NAPHTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2005-11-10 | — | — | WO | disclosed |
| US-5183821-A | Administering anticarcinogenic agents | LABORATORIES KNOLL, S.A. (ES) | 1993-02-02 | — | — | US | disclosed |
| US-5183821-A | Administering anticarcinogenic agents | LABORATORIES KNOLL, S.A. (ES) | 1993-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111367-A1 | Sulfur-containing naphthalimide derivatives | HCCS, SQOR, MKI67 | MEN1 3613/4885KMT2A 1942/4885PKM 2061/4885 |
| US-20080234287-A1 | SULFUR-CONTAINING NAPHTHALIMIDE DERIVATIVES | HCCS, SQOR, MKI67 | MEN1 3613/4885KMT2A 1942/4885PKM 2061/4885 |
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | NPM1, NAPRT, NUTF2 | MEN1 2716/4885KMT2A 2924/4885PKM 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.